AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
RCEL - AVITA Medical, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.00
DETAILS
HIGH:
$10.00
LOW:
$6.00
MEDIAN:
$8.00
CONSENSUS:
$8.00
UPSIDE:
74.67%
Stock News
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m.
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.
Avita Medical Q1 Earnings Call Highlights
Avita Medical NASDAQ: RCEL reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
AVITA Medical Reports First Quarter 2026 Financial Results
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026.
AVITA Medical Names Cary Vance as Chief Executive Officer
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately.
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL ® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration (“TGA”) and has been listed on New Zealand's Web Assisted Notification of Devices (“WAND”) database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.
AVITA Medical to Announce First Quarter 2026 Financial Results
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical Inc. (“AVITA Medical” or the “Company”) (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA).
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wounds.
AVITA Medical, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. , (“ AVITA " or the "Company") ( NASDAQ : RCEL ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcomes
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of “Hold” from Analysts
Avita Medical Inc. (NASDAQ: RCEL - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O'Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Price Targets
Avita Medical upgraded to Buy from Hold at Lake Street
$6.00
(was $4.36)
Lake Street
Avita Medical stock pullback creates buying opportunity, says Northland
$10.00
(was $3.86)
Northland Securities
Avita Medical price target raised to $3.50 from $3 at Lake Street
$3.50
(was $3.60)
Lake Street
Avita Medical downgraded to Hold from Buy at Lake Street
$4.00
(was $5.38)
Frank Takkinen
·
Lake Street
Avita Medical price target lowered to $14 from $20 at Lake Street
$14.00
(was $14.06)
Brooks O'Neil
·
Lake Street
Piper Sandler Downgrades Avita Medical Ltd. (RCEL) to Neutral
$9.00
(was $8.35)
Matt O'Brien
·
Piper Sandler